Is KYTX stock a buy?
What Is The Conclusion?
Right now our advanced algorithms say:
Do the analyst corps agree?
Interesting Questions and Easy Answers!
We cannot find any recorded dividends paid in our systems.
Sorry, we do not have any analyst data for this ticker
We cannot find data for Kyverna Therapeutics, 10 years ago, but if you had invested on Wednesday 7th of February 2024 when the price was $0.0000, you would have made a profit of $7.34 per share or 73 399 900.00%
Yes, the average daily trading liquidity for Kyverna Therapeutics, is $5.75 million. You should therefore be able to get in and out of your positions relatively fast.
Kyverna Therapeutics, has N/A of the business financed by loans. This puts the company at N/A risk in periods of high inflation where borrowing costs usually go up. With a N/A cash flow to debt ratio of 0, the company's ability to pay off the debt is N/A. The company is still not profitable, and high inflation will make it harder to become profitable as costs increase and consumer spending decreases.
We have calculated the inflation risk for Kyverna Therapeutics, to be low [0 out of 1]